학술논문

Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Document Type
Journal
Source
JOURNAL OF HEPATOLOGY; JUL 2022, 77 pS10-pS10, 1p. Supplement: 1
Subject
Language
English
ISSN
16000641